Multicenter closed-loop insulin delivery study points to challenges for keeping blood glucose in a safe range by a control algorithm in adults and adolescents with type 1 diabetes from various sites.

BACKGROUND The Control to Range Study was a multinational artificial pancreas study designed to assess the time spent in the hypo- and hyperglycemic ranges in adults and adolescents with type 1 diabetes while under closed-loop control. The controller attempted to keep the glucose ranges between 70 and 180 mg/dL. A set of prespecified metrics was used to measure safety. RESEARCH DESIGN AND METHODS We studied 53 individuals for approximately 22 h each during clinical research center admissions. Plasma glucose level was measured every 15-30 min (YSI clinical laboratory analyzer instrument [YSI, Inc., Yellow Springs, OH]). During the admission, subjects received three mixed meals (1 g of carbohydrate/kg of body weight; 100 g maximum) with meal announcement and automated insulin dosing by the controller. RESULTS For adults, the mean of subjects' mean glucose levels was 159 mg/dL, and mean percentage of values 71-180 mg/dL was 66% overall (59% daytime and 82% overnight). For adolescents, the mean of subjects' mean glucose levels was 166 mg/dL, and mean percentage of values in range was 62% overall (53% daytime and 82% overnight). Whereas prespecified criteria for safety were satisfied by both groups, they were met at the individual level in adults only for combined daytime/nighttime and for isolated nighttime. Two adults and six adolescents failed to meet the daytime criterion, largely because of postmeal hyperglycemia, and another adolescent failed to meet the nighttime criterion. CONCLUSIONS The control-to-range system performed as expected: faring better overnight than during the day and performing with variability between patients even after individualization based on patients' prior settings. The system had difficulty preventing postmeal excursions above target range.

[1]  Eyal Dassau,et al.  Pilot Studies of Wearable Outpatient Artificial Pancreas in Type 1 Diabetes , 2012, Diabetes Care.

[2]  F. El-Khatib,et al.  Blood Glucose Control in Type 1 Diabetes With a Bihormonal Bionic Endocrine Pancreas , 2012, Diabetes Care.

[3]  E. Atlas,et al.  MD-Logic Artificial Pancreas System , 2010, Diabetes Care.

[4]  Eric Renard,et al.  Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-period, observational, multicenter study. , 2010, Diabetes technology & therapeutics.

[5]  R.S. Parker,et al.  A model-based algorithm for blood glucose control in Type I diabetic patients , 1999, IEEE Transactions on Biomedical Engineering.

[6]  Eyal Dassau,et al.  Coordinated Basal—Bolus Infusion for Tighter Postprandial Glucose Control in Insulin Pump Therapy , 2009, Journal of diabetes science and technology.

[7]  Claudio Cobelli,et al.  Diurnal Pattern of Insulin Action in Type 1 Diabetes , 2013, Diabetes.

[8]  Eyal Dassau,et al.  Modular Artificial β-Cell System: A Prototype for Clinical Research , 2008 .

[9]  Ahmad Haidar,et al.  Closed-Loop Basal Insulin Delivery Over 36 Hours in Adolescents With Type 1 Diabetes , 2013, Diabetes Care.

[10]  Janet M. Allen,et al.  Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies , 2011, BMJ : British Medical Journal.

[11]  E. Atlas,et al.  Nocturnal glucose control with an artificial pancreas at a diabetes camp. , 2013, The New England journal of medicine.

[12]  Irl B Hirsch,et al.  Use of a "fuzzy logic" controller in a closed-loop artificial pancreas. , 2013, Diabetes technology & therapeutics.

[13]  David M Nathan,et al.  Autonomous and continuous adaptation of a bihormonal bionic pancreas in adults and adolescents with type 1 diabetes. , 2014, The Journal of clinical endocrinology and metabolism.

[14]  Janet M. Allen,et al.  Day and Night Closed-Loop Control in AdultsWith Type 1 Diabetes A comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management , 2013 .

[15]  Howard C. Zisser,et al.  Feasibility of Outpatient Fully Integrated Closed-Loop Control , 2013, Diabetes Care.

[16]  Patrick McElduff,et al.  Both Dietary Protein and Fat Increase Postprandial Glucose Excursions in Children With Type 1 Diabetes, and the Effect Is Additive , 2013, Diabetes Care.

[17]  C. Cobelli,et al.  Artificial Pancreas Goes Outpatient: A New Diabetes Ecosystem , 2013, Journal of diabetes science and technology.

[18]  Janet M. Allen,et al.  Day and Night Closed-Loop Control in Adults With Type 1 Diabetes , 2013, Diabetes Care.

[19]  Thomas Peyser,et al.  A new-generation continuous glucose monitoring system: improved accuracy and reliability compared with a previous-generation system. , 2013, Diabetes technology & therapeutics.

[20]  Robert G. Sutherlin,et al.  A Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes , 2010, Science Translational Medicine.

[21]  G. Steil,et al.  Feasibility of Automating Insulin Delivery for the Treatment of Type 1 Diabetes , 2006, Diabetes.

[22]  Eyal Dassau,et al.  Control to Range for Diabetes: Functionality and Modular Architecture , 2009, Journal of diabetes science and technology.

[23]  Claudio Cobelli,et al.  Closed loop developments to improve glucose control at home. , 2013, Diabetes research and clinical practice.

[24]  L. Magni,et al.  First Use of Model Predictive Control in Outpatient Wearable Artificial Pancreas , 2014, Diabetes Care.

[25]  C. Cobelli,et al.  Artificial Pancreas: Past, Present, Future , 2011, Diabetes.

[26]  E. Atlas,et al.  The “Glucositter” overnight automated closed loop system for type 1 diabetes: A randomized crossover trial , 2013, Pediatric Diabetes.

[27]  Anirban Roy,et al.  Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes , 2014 .

[28]  L. Magni,et al.  Model Predictive Control of Type 1 Diabetes: An in Silico Trial , 2007, Journal of diabetes science and technology.

[29]  Pierre-Yves Richard,et al.  A Closed-Loop Artificial Pancreas Using a Proportional Integral Derivative with Double Phase Lead Controller Based on a New Nonlinear Model of Glucose Metabolism , 2013, Journal of Diabetes Science and Technology.

[30]  Anirban Roy,et al.  The effect of insulin feedback on closed loop glucose control. , 2011, The Journal of clinical endocrinology and metabolism.

[31]  Roman Hovorka,et al.  Evaluation of a portable ambulatory prototype for automated overnight closed‐loop insulin delivery in young people with type 1 diabetes , 2012, Pediatric diabetes.

[32]  L. Magni,et al.  Multinational Study of Subcutaneous Model-Predictive Closed-Loop Control in Type 1 Diabetes Mellitus: Summary of the Results , 2010, Journal of diabetes science and technology.

[33]  Stephen D Patek,et al.  Hypoglycemia Prevention via Pump Attenuation and Red-Yellow-Green “Traffic” Lights Using Continuous Glucose Monitoring and Insulin Pump Data , 2010, Journal of diabetes science and technology.

[34]  K. Turksoy,et al.  Multivariable adaptive closed-loop control of an artificial pancreas without meal and activity announcement. , 2013, Diabetes technology & therapeutics.

[35]  Howard C. Zisser,et al.  Fully Integrated Artificial Pancreas in Type 1 Diabetes , 2012, Diabetes.

[36]  J. Leahy,et al.  Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas , 2008 .

[37]  Anirban Roy,et al.  Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes , 2012, Diabetes Care.

[38]  Marc D. Breton,et al.  Modular Closed-Loop Control of Diabetes , 2012, IEEE Transactions on Biomedical Engineering.

[39]  D. B. Keenan,et al.  The Use of an Automated, Portable Glucose Control System for Overnight Glucose Control in Adolescents and Young Adults With Type 1 Diabetes , 2012, Diabetes Care.